Skip to main content

PD-1/PD-L1 Immunotherapy Market Opportunities and Forecast 2020-2030

 Cancer immunotherapy has significantly advanced in the past few years, and PD-1/PD-L1 immunotherapy has emerged out as one of the most prominent therapies. Many clinical trials have proved their significance, and many are still underway to find other cancers which can be treated with this therapy. These therapies have shown exceptional results in combination with other therapies with reasonable toxicity profile. Further, dynamic immunologic studies, along with genetics and epigenetics in the human cancer microenvironment, are expected to guide the development of different combination therapies and generate novel insight into how the human immune system responds to and is shaped by a variety of tumor types.

Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.

The unmet medical needs in the field of treatment of cancer is significantly driving the growth of this market. Other factors driving the growth include the high prevalence of cancer and increasing expedited approvals by FDA.

Despite the various factors that are influencing the growth of this market, there are several key issues that are needed to be addressed to facilitate future growth. The relatively high total costs of development and usage of PD-1/PD-L1 inhibitors and reimbursement policies are restraining the growth of this market.

Market Segmentation

•    Type: PD-1 and PD-L1 inhibitors

•    Application: Non-Small Cell Lung Cancer, Esophageal Cancer, Urothelial Carcinoma, Hepatocellular Carcinoma, Small Cell Lung Cancer, and Others


Regional Segmentation

•    North America – U.S., Canada

•    Europe – Germany, France, Italy, U.K., Spain, Rest-of-Europe

•    Asia-Pacific – Japan, China, India, Australia, South Korea, Rest-of-Asia-Pacific

•    Latin America – Brazil, Mexico, Rest-of-Latin America

•    Rest-of-the-World


Growth Drivers

•    Rising Prevalence of Cancer

•    Unmet Medical Needs of Metastatic Cancer Patients

•    Advancements Made in the Field of Precision Medicine and Immuno-Oncology

•    Rising Awareness Among People for the Treatment of Cancer

•    Increasing Research and Development in the Field of Oncology

•    Increase in Disposable Income


Market Challenges

•    Adverse Effects of PD-1/PD-L1 Immunotherapy

•    Payment Policy and Reimbursement Issue

•    High Development of New Therapy


Market Opportunities

•    Developing Healthcare Infrastructure in Emerging Economies


Key Companies Profiled

AstraZeneca Plc, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Jiangsu HengRui Medicine Co. Ltd., Innovent Biologics, Inc., Sanofi S.A., Merck KGaA, Regeneron Pharmaceuticals Inc., BeiGene,  Ltd., GlaxoSmithKline Plc, Eli Lilly & Company, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Request a Sample - https://bisresearch.com/requestsample?id=971&type=download

Labels:

Comments

Post a Comment

Popular posts from this blog

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: •     Industry Analysis    ...
Post a Comment
Read more

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Hyperspectral Imaging Market Projections , Upcoming Trends Focus on Long-Term Impact of Covid-19 and Forecast By 2027

  The global  hyperspectral imaging market  was estimated to be at $791.2 million in 2021, which is expected to grow with a CAGR of 13.17% and reach $1,640.3 million by 2027.The growth in the global hyperspectral imaging market is expected to be primarily driven by increased awareness of the technology in different sectors such as agriculture, healthcare, and mining. The hyperspectral imaging technology has great potential, and the market is anticipated to grow during the forecast period owing to the widespread applications of HSI, increasing investments for RD activities, increasing demand from military and defense sectors, increased food safety concerns, and increasing awareness regarding early diagnosis of diseases.   COVID-19 Impact and Post-COVID-19 Scenario The COVID-19 pandemic had a debilitating impact on the global ecosystem. The pandemic led to a shutdown of production facilities, which do not come under essential goods, which led to a negative impact on se...
Post a Comment
Read more